Skip to main content

Table 5 Summary findings of sensitivity analyses for 177Lu-Dotatate versus octreotide LAR 60 mg in GI-NET

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Analysis Costs, GBP Quality-adjusted life expectancy, QALYs ICER, GBP per QALY % change from base case
177Lu-Dotatate Octreotide 60 mg Delta 177Lu-Dotatate Octreotide 60 mg Delta
Base case analysis 84,990 49,289 35,701 3.25 1.92 1.33 26,830
Time horizon 5 years 75,715 44,896 30,818 2.37 1.71 0.66 47,013 75.23
Time horizon 10 years 86,710 48,758 37,951 2.95 1.89 1.06 35,986 34.13
Discount rate 1.5% clinical outcomes, 6% costs 80,896 46,711 34,185 3.48 2.00 1.48 23,104 −13.88
Efficacy; using MTC data for 177Lu-Dotatate versus octreotide 89,728 49,022 40,706 3.09 1.90 1.19 34,478 28.51
Efficacy; using MTC data for 177Lu-Dotatate versus everolimus (RADIANT-4) 89,728 68,045a 21,683 3.09 2.53a 0.56 39,169 45.99
PFS utility from NETTER-1 84,990 49,289 35,701 3.14 1.90 1.24 28,750 7.16
PFS utility from real world studya 84,990 49,289 35,701 3.26 1.94 1.32 26,855 0.09
177Lu-Dotatate RDI 86.4% (NETTER-1) 86,370 49,289 37,081 3.25 1.92 1.33 27,866 3.86
Including palliative care costs 91,354 63,464 27,890 3.16 1.73 1.43 19,544 −27.15
  1. aEverolimus
  2. bData from analysis of registry data from Guy’s and St Thomas’ Hospital, London. AAA data on file
  3. HR hazard ratio, ICER incremental cost-effectiveness ratio, MTC mixed treatment comparison, PFS progression-free survival, QALY quality-adjusted life year, RDI relative dose intensity